|
Video: What is a Stock Split?
|
|
Solid Biosciences is a life science company focused on developing a portfolio of neuromuscular and cardiac programs, including SGT-003, a gene therapy candidate, for the treatment of Duchenne muscular dystrophy; AVB-202-TT, a gene therapy program for the treatment of Friedreich's ataxia; AVB-401, a gene therapy program for the treatment of BCL-2-associated athanogene 3-mediated dilated cardiomyopathy (DCM); and additional assets for the treatment of undisclosed cardiac diseases. Co. also has two pipeline programs, AVB-501 for DCM and AVB-601 for hypertrophic, that are both in preclinical development to treat undisclosed cardiac indications. According to our SLDB split history records, Solid Biosciences has had 1 split. | |
|
Solid Biosciences (SLDB) has 1 split in our SLDB split history database. The split for SLDB took place on October 28, 2022. This was a 1 for 15 reverse split, meaning for each 15 shares of SLDB owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 66.6666666666667 share position following the split.
When a company such as Solid Biosciences conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the SLDB split history from start to finish, an original position size of 1000 shares would have turned into 66.6666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Solid Biosciences shares, starting with a $10,000 purchase of SLDB, presented on a split-history-adjusted basis factoring in the complete SLDB split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
01/29/2018 |
|
End date: |
03/27/2024 |
|
Start price/share: |
$355.50 |
|
End price/share: |
$14.25 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-95.99% |
|
Average Annual Total Return: |
-40.68% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$401.02 |
|
Years: |
6.16 |
|
|
|
Date |
Ratio |
10/28/2022 | 1 for 15 |
|
|